Experimental Gene Therapy for Giant Axonal Neuropathy Shows Promise in NIH Clinical Trial
March 20, 2024 -- An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Conditions: CLL/SLL Interventions: Drug: Lisaftoclax (APG-2575); Drug: Acalabrutinib; Drug: Fludarabine; Drug: Cyclophosphamide ,CTX; Drug: Rituximab; Drug: Chlorambucil Sponsors: Ascentage Pharma Group Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
Conditions: Primary Open-angle Glaucoma Interventions: Drug: TimoD implant; Device: Injector system Sponsors: EyeD Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
CAMBRIDGE, Mass., March 19, 2024. The Bill& Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 20, 2024 Category: Pharmaceuticals Source Type: clinical trials

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG ®
Conditions: Surgical Site Infection; Staphylococcus Aureus Infection; Pseudomonas Aeruginosa Infection; Bacterial Infections; Surgical Wound Infection Interventions: Drug: IMP; Drug: Placebo Sponsors: MB PHARMA s.r.o. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuation
JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials

Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Model
March 18, 2024 -- Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), successfully alleviated pain and inflammation in a rodent model of endometriosis, according to researchers funded by the National Institutes of Health (NIH). They chose the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 18, 2024 Category: Pharmaceuticals Source Type: clinical trials

The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients
Conditions: Hemodialysis Patients Interventions: Drug: Pumpkin Seed Oil " Ronkin ®, KMT PHARMA, Egypt. " Sponsors: Ain Shams University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

Efficacy and Safety of Gemlapodect in Adults and Adolescents With Tourette Syndrome
Conditions: Tourette Syndrome Interventions: Drug: Gemlapodect; Drug: Placebo Sponsors: Noema Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions
Conditions: Healthy Vollunteer Interventions: Drug: Alfuzosin Hydrochloride 10 mg; Drug: Xatral ® XL 10 mg Sponsors: Pharma Nueva Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials
NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front. myTomorrows is a global health technology company shaping the future landscape of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 15, 2024 Category: Pharmaceuticals Source Type: clinical trials

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: Tralokinumab + TCS; Drug: Placebo + TCS Sponsors: LEO Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Combining EPI-7386 w/ Enzalutamide & Androgen Deprivation Therapy for Newly Diagnosed Prostate Cancer
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma Interventions: Drug: EPI-7386; Drug: Enzalutamide; Drug: Androgen Deprivation Therapy (ADT) Sponsors: Pedro Barata, MD, MSc; ESSA Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials